Immunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the thirteen brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $65.64.

IMCR has been the topic of a number of recent analyst reports. Mizuho lowered shares of Immunocore from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Morgan Stanley restated an "equal weight" rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Guggenheim downgraded Immunocore from a "buy" rating to a "neutral" rating in a report on Monday, October 7th. UBS Group started coverage on shares of Immunocore in a research note on Thursday, October 24th. They set a "sell" rating and a $24.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research note on Monday.

Hedge Funds Weigh In On Immunocore

Institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its holdings in shares of Immunocore by 10.5% during the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock worth $219,430,000 after buying an additional 668,382 shares during the last quarter. Primecap Management Co. CA increased its stake in Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock worth $76,954,000 after acquiring an additional 520,950 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Immunocore by 124.4% in the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company's stock worth $20,366,000 after purchasing an additional 333,167 shares during the period. Two Sigma Advisers LP lifted its stake in shares of Immunocore by 65.6% in the 3rd quarter. Two Sigma Advisers LP now owns 757,700 shares of the company's stock valued at $23,587,000 after purchasing an additional 300,200 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock valued at $17,007,000 after purchasing an additional 109,206 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Stock Performance

Shares of NASDAQ IMCR traded up $0.97 during trading hours on Thursday, reaching $32.61. The stock had a trading volume of 196,391 shares, compared to its average volume of 258,052. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a fifty-two week low of $27.69 and a fifty-two week high of $76.98. The firm has a 50-day moving average of $30.53 and a 200-day moving average of $33.22. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -34.33 and a beta of 0.76.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. During the same quarter in the prior year, the firm earned ($0.59) EPS. Immunocore's revenue for the quarter was up 23.7% on a year-over-year basis. Equities research analysts predict that Immunocore will post -0.94 earnings per share for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.